

PATENT USSN 09/701,623 Docket No. <u>115</u>1-4153US1

Express Mail: <u>EV 094 904 427US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Chang Yi WANG et al

RECEIVED

Serial No

09/701,623

JUN 2 6 2002

Int. Filing Date

June 21, 1999

TECH CENTER 1600/2900

For

PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT

OF ALLERGY

Group Art Unit

1644

Examiner

Margaret Megan Jamoz, Ph.D.

Commissioner for Patents Washington, DC. 20231

AMENDMENT AND RESPONSE PURSUANT TO 37 C.F.R. § 1.115

Sir:

This is in response to the Office Action issued June 6, 2002.

RESPONSE

The Examiner indicated that the response to the restriction requirement submitted on April 2, 2002 was not complete for not having made an election of the claims.

Applicant provisionally elects claims 1-2 and 19-20 of Group I and provisionally cancel claims 3-18, 21-28 pending the request for withdrawal of the restriction requirement.

The election is made to meet the statutory requirements. However, as pointed out in the previous response, the restriction requirement is traversed. Applicant had pointed out that the restriction requirement made was wrong. The previous Examiner failed to recognize that the claims are directed to a single inventive concept, the use of a single epitope in IgE-CH3 domain conjugated to a Th

PATENT USSN 09/701,623 Docket No. <u>1151-4153US1</u>

Express Mail: EV 094 904 427US

epitope to generate antibodies against IgE for the treatment of allergies. The reasons for the traversal and request for withdrawal of the restriction requirement was stated in the response submitted on April 2, 2002 and will not be repeated here.

An amendment of Claims 10-13 was submitted with the previous response. Entry of the amendment is requested. A telephone call was made to the present Examiner, whose courtesy is deeply appreciated.

Respectfully submitted,

Registration No. 29,323

Maria C.H. Lin

Dated: June 20, 2002

CORRESPONDENCE ADDRESS: MORGAN & FINNEGAN LLP 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Facsimile

Direct Line: 212-415-8745